After years of seeing cancer immunotherapies fall short of their full potential, industry oncology veterans are taking a new tack. Under the banner of Akrevia Therapeutics Inc., they've put together a $30 million series A financing "with the aim of going big," Tim Clackson, president and head of R&D for the new venture, told BioWorld.